We have shown that MARCH1 is a tumor promoter that regulates the phosphoinositide-3-kinase/protein kinase B (PI3K/AKT)/β-catenin signaling pathway and might be a potential molecular therapeutic target in HCC [10]. The gene discussed is AKT1; the disease is neoplasm.